CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path - Yahoo Finance

Business

12 hours ago 16 Views 05 Comment 1.5k Share

Listen to this article

Voice:

The firm highlighted Capricor's plan to amend its biologics license application from the Hope-3 study for Deramiocel.
Capricor reported a second-quarter net loss of $0.70 per share,… [+2454 chars]

Arnab Paul

Read Full Article View All Articles

Comments

No comments yet. Be the first to comment!

Stay Connected

13,977 Fans 21,798 Followers 7,999 Subscribers 19,764 Followers 31,999 Connections 5,000 Followers 9,000 Subscribers 18,000 Followers 2,500 Karma Join Chat Join Channel

Your trusted source for breaking news, in-depth analysis, and comprehensive coverage of today's most important stories.

Stay Informed with Our Newsletter

Get daily updates on breaking news, exclusive interviews, and special features delivered to your inbox.

Get In Touch

Have a news tip or want to get in touch with our editorial team? We're here to help.

Our Office

Plot C3-C Jaypee Wishtown Sector 129 Noida Uttar Pradesh 201304 India

Email Address

[email protected]

Phone Number

+91-11-26446666

Connect With Us

Quick Links

Home About Us Contact Us Advertise E-Newspaper

Videos Fact Check RSS Feed Track Order Archives

CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path - Yahoo Finance

Listen to this article

Share:

Arnab Paul

Leave A Comment

Comments

Stay Connected

Stay Informed with Our Newsletter

Get In Touch

Our Office

Email Address

Phone Number

Connect With Us

Quick Links

Crime & Justice

Browse All Categories

Politics

Business

Health

Technology

Entertainment

Sports

World

Featured

More Categories